

# Supplementary File

**Table S1.** Observed progression-free survival.

	<i>n</i> Patients	<i>n</i> Events	Median PFS, mo (95% CI)	One-Year PFS, % (95% CI)
Total treated cohort <sup>1</sup>	177	139	7.1 (6.3-9.4)	35.6 (28.7-44.0)
HMA all lines <sup>2</sup>	74	65	5.1 (3.4-9.2)	26.9 (18.2-39.6)
HMA ≥2 <sup>nd</sup> line <sup>3</sup>	33	31	3.4 (2.0-6.3)	12.6% (5.0-31.5)
HMA 1 <sup>st</sup> line <sup>4</sup>	39	32	9.4 (4.2-14.5)	40.6 (27.3-60.2)
ICT 1st line <sup>5</sup>	103	74	8.0 (6.9-14.5)	41.8 (32.5-53.7)

<sup>1</sup> Includes HMA 1<sup>st</sup> line, HMA ≥ 2<sup>nd</sup> line, and ICT 1<sup>st</sup> line;

<sup>2</sup> Data on PFS was not available for *n* = 14 patients;

<sup>3</sup> Data on PFS was not available for *n* = 12 patients;

<sup>4</sup> Data on PFS was not available for *n* = 2 patients;

<sup>5</sup> Data on PFS was not available for *n* = 19 patients.

**Table S2.** Observed overall survival in the overall sample and in treatment subgroups.

	<i>n</i> Patients	<i>n</i> Events	Median OS, mo (95% CI)	One-Year Survival, % (95% CI)
Total treated cohort <sup>1</sup>	205	142	11.1 (9.8-14.3)	49.1 (42.2-57.2)
HMA all lines <sup>2</sup>	84	58	12.3 (9.8-14.3)	52.5 (42.1-65.5)
HMA ≥2 <sup>nd</sup> line <sup>3,*</sup>	41	28	9.8 (4.6-13.5)	38.0 (24.2-59.6)
HMA 1 <sup>st</sup> line <sup>4,*</sup>	41	29	13.7 (12.3-20.5)	65.8 (52.2-82.9)
ICT 1st line <sup>5</sup>	121	84	10.5 (9.1-20.0)	46.7 (37.9-57.5)

<sup>1</sup> Includes HMA 1<sup>st</sup> line, HMA ≥ 2<sup>nd</sup> line, and ICT 1<sup>st</sup> line;

<sup>2</sup> Data on OS was not available for *n* = 4 patients;

<sup>3</sup> Data on OS was not available for *n* = 1 patient;

<sup>4</sup> Data on OS was not available for *n* = 1 patient;

<sup>5</sup> Data on OS was not available for *n* = 1 patient;

\* Data on line of treatment was not available for *n* = 2 patients.

**Table S3.** Distribution of causes of death by treatment group (censored at BMT).

Cause of Death	HMA ( <i>n</i> =84 <sup>1</sup> )	ICT (3+7) ( <i>n</i> =121 <sup>2</sup> )	<i>p</i> -Value (Chi-Square-Test)
AML progression, <i>n/n</i> (%)	31/58 (53)	55/84 (65)	0.269
Infection, <i>n/n</i> (%)	10/58 (17)	11/84 (13)	0.465
Others, <i>n/n</i> (%)	6/58 (10)	6/84 (7)	0.467
Unknown, <i>n/n</i> (%)	11/58 (19)	12/84 (14)	0.384
Total deaths, <i>n/n</i> (%)	58/84 (69)	84/121 (69)	1

<sup>1</sup> Survival Data was not available for *n* = 4 patients. <sup>2</sup> Survival Data was not available for *n* = 1 patient.